Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Blood
Personen und Körperschaften: Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Flinn, Ian W., Burger, Jan A., Tran, Anh, Clow, Fong, James, Danelle F., Graef, Thorsten, Friedberg, Jonathan W., Rai, Kanti, O’Brien, Susan
In: Blood, 125, 2015, 19, S. 2915-2922
Format: E-Article
Sprache: Englisch
veröffentlicht:
American Society of Hematology
Schlagwörter:
Cell Biology
Hematology
Immunology
Biochemistry
Details
Zusammenfassung: <jats:title>Key Points</jats:title> <jats:p>Ibrutinib was well tolerated when administered with BR CIT in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Ibrutinib added to CIT was associated with a high degree of clinical activity that compares favorably to historical reports of CIT alone.</jats:p>
Umfang: 2915-2922
ISSN: 0006-4971
1528-0020
DOI: 10.1182/blood-2014-09-585869